Infectious Diseases

Overview

The aim of the seven groups of this area is to improve the outcomes of patients with infectious diseases. The Epidemiology and Public Health group is mainly focused on the epidemiology and prevention of healthcare acquired infections, transmissible infections and on the new preventive vaccines. The Infectious Diseases group focuses on improving the strategies of clinical problems observed in clinical practice. Microbiology studies mechanisms of resistance to antimicrobials, pathogenicity, taxonomy and epidemiology, and infectious diseases diagnostics.

The CRIPS group focuses on the most prevalent aspects of infections in the intensive care unit (ICU), while SODIR group works in the areas of shock, organ dysfunction and resuscitation.

There is also a group focused on infection in immunocompromised pediatric patients, and a group from the CIBBIM-Nanomedicine interested in the synthesis, characterization and applications of engineered inorganic nanoparticles in the field of medicine.

Publications

236

total

1,029.655

impact factor

4.363

average impact factor

Director: Benito Almirante

team

group-zoom

zoom

group-download

download

During 2017 the Research Group on Infectious Diseases has developed projects related to new therapeutic options for multi-resistant bacterial infections, like electric stimulation to eradicate microorganisms in the biofilms of prosthetic devices, the epidemiology and therapy of tropical diseases in our country, with the epidemiology and prognosis of serious infections in immunocompromised patients and assessment of new strategies for antiretroviral treatment. Our group has published 94 articles in indexed biomedical journals and has obtained 5 projects with competitive funding (about 600.00€ of amount awarded).
Our group has established research synergies with various national and international groups, through their participation in 3 Cooperative Research Networks from the Health Institute Carlos III (REIPI, RIS and RICET), collaboration agreements with organizations such as IBEC, and agreements with international research groups in the field of international health. During 2017 our group has consolidated the new line of research in the field of basic and translational research related to HIV eradication of patients infected with this virus.

99

total

423^.523

impact factor

4^.278

average impact factor

SELECTED ARTICLES

Fernandez-Hidalgo N, Ribera A, Larrosa MN, Viedma E, Origuen J, de Alarcon A, Farinas MC, Saez C, Pena C, Munez E, Garcia Lopez MV, Gavalda J, Perez-Montarelo D, Chaves F, Almirante B.
Impact of Staphylococcus aureus phenotype and genotype on the clinical characteristics and outcome of infective endocarditis. A multicenter, longitudinal, prospective, observational study.
Clin Microbiol Infect. 2017 Dec 18. pii: S1198-743X(17)30675-4.
PMID: 29269091
DOI: 10.1016/j.cmi.2017.12.002
IF 5,292
Peghin M, Hirsch HH, Len O, Codina G, Berastegui C, Saez B, Sole J, Cabral E, Sole A, Zurbano F, Lopez-Medrano F, Roman A, Gavalda J
Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study.
Am J Transplant. 2017 May;17(5):1304-1312. Epub 2016 Oct 14.
PMID: 27615811
DOI: 10.1111/ajt.14042
IF: 6,165
Grau-Exposito J, Serra-Peinado C, Miguel L, Navarro J, Curran A, Burgos J, Ocana I, Ribera E, Torrella A, Planas B, Badia R, Castellvi J, Falco V, Crespo M, Buzon MJ.
A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.
MBio. 2017 Jul 11;8(4). pii: e00876-17.
DOI: 10.1128/mBio.00876-17.
PMID: 28698276
IF: 6,956
Pulido F, Ribera E, Lagarde M, Perez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodriguez-Gomez FJ, Tellez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR.
Dual therapy with darunavir and ritonavir plus lamivudine versus triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of HIV-1 viral suppression: randomised, open label, non-inferiority DUAL-GESIDA 8014-RIS-EST45 trial.
Clin Infect Dis. 2017 Nov 29;65(12):2112-2118.
DOI: 10.1093/cid/cix734.
PMID: 29020293
IF: 8,216
Beloin C, Fernández-Hidalgo N, Lebeaux D.
Understanding biofilm formation in intravascular device-related infections.
Intensive Care Med. 2017 Mar;43(3):443-446 Epub 2016 Aug 6.
DOI: 10.1007/s00134-016-4480-7
PDMI: 27497588
IF: 12.02

View all publications